RxDoctor Payments Data

Rajdeep Singh, MD

Neurology · Charlotte, NCNPI 1568628691

Payments from drug & device makers

$31,729in general payments, 2019–2025

Across 57 payments — averaging $556.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$18K
  • Catalyst Pharmaceuticals, Inc.$5K
  • Sunovion Pharmaceuticals Inc.$3K
  • SK Life Science, Inc.$2K
  • Neuropace, Inc.$1K
  • Medtronic$952
  • plus $1K from 7 others

What the payments were for

  • Speaking & faculty fees$5,95044%
  • Travel & lodging$3,41525%
  • Food & beverage$4,04630%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,729 in reported general payments places this provider in the 75th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$31,770
Medicare patients
145
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate110$248,293
XcopriCenobamate131$171,689
BriviactBrivaracetam84$137,776
Lamictal XrLamotrigine23$98,322
FycompaPerampanel50$66,211
VimpatLacosamide42$48,542
Trokendi XrTopiramate12$39,370
Keppra XrLevetiracetam17$34,633
Lacosamide222$31,011
NayzilamMidazolam25$30,652
LamictalLamotrigine14$16,332
Nurtec OdtRimegepant Sulfate17$15,928
Clobazam55$13,697
Levetiracetam234$7,733
Lamotrigine ErLamotrigine20$5,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$3,040$248,293110 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$750$216,970151 claims
SK Life Science, Inc.Xcopri$1,674$171,689131 claims
Eisai Inc.Fycompa$120$66,21150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →